The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. ⋯ Etanercept provided clinically meaningful benefit to patients with chronic plaque psoriasis, with no apparent decrease in efficacy after dose reduction.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
There is a need for safe and effective alternative treatments for patients with moderate to severe psoriasis. ⋯ Oral pimecrolimus produces a dose-dependent reduction in psoriasis severity, with doses of 20 mg and 30 mg b.d. being the most effective and well tolerated.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Psoriasis is a chronic disease that significantly diminishes the health-related quality of life (HRQOL). Infliximab is a chimeric, tumour necrosis factor alpha monoclonal antibody that has been shown to improve the signs and symptoms of plaque psoriasis. ⋯ Infliximab induction therapy resulted in significant improvement in HRQOL in patients with severe psoriasis.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Imiquimod is an immune response modifier that acts through toll-like receptor 7 to induce cytokine production and a subsequent innate and adaptive cell-mediated immune response. Clinical studies have demonstrated clinical and histological clearance of superficial basal cell carcinoma (sBCC) after treatment with imiquimod 5% cream. ⋯ Imiquimod 5% cream administered 7 x/week for 6 weeks is a safe and effective treatment for sBCC when compared with vehicle cream.
-
Letter Randomized Controlled Trial Clinical Trial
Utility of studying the ocular surface in patients with acne vulgaris treated with oral isotretinoin: a randomized controlled trial.